Kodiak Sciences :
KOD
KOD
Stock Data
$43.96
$0.48 (1.10%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Kodiak Sciences Inc is a pioneering biopharmaceutical company focused on developing innovative therapies for retinal diseases. Its flagship product, tarcocimab tedromer, is making strides in clinical studies to address conditions like wet age-related macular degeneration and diabetic macular edema. Additionally, Kodiak is exploring treatments for inflammatory retinal diseases and dry AMD with its early-stage candidates. Founded in 2009 and evolving from Oligasis, LLC, Kodiak is based in Palo Alto, California, pushing the boundaries of retinal disease treatment.
All Kodiak Sciences Articles
6 Articles